Nanopareil is now a part of
You will be automatically re-directed...
Since 2019, the Nanopareil team has been working to deliver innovative, functionalized nanofiber chromatography technology for advanced gene therapies. The legacy Nanopareil nanofiber chromatography technology was designed with a large open pore structure for high absorptive capacity and uniform flow distribution to enable functional improvements versus resin-based purification methods. The technology has since been optimized to provide a platform technology for downstream processing.
In late 2020, Gamma Biosciences acquired the technology to focus on industrialization. This partnership, including alignment with Gamma portfolio company, Astrea Bioseparations, has been a strong complement as we collaborate to develop affinity nanofiber products to bring a paradigm shift in the world of downstream chromatography.
We are driven by a mission to create chromatography products uniquely suited for purifying gene therapy biomolecules by delivering higher binding capacities, faster throughput, and lower cost of goods vs. traditional resin-based chromatography.
Our vision is to industrialize an enabling nanofiber chromatography platform that helps to realize reliable, affordable production of the next generation of biopharmaceuticals.